AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference
AnaptysBio, a clinical-stage biotechnology company (Nasdaq: ANAB), has announced that CEO Hamza Suria will present at the 2020 Jefferies London Virtual Healthcare Conference on November 17, 2020, at 12:35 p.m. ET. The conference will be held virtually, with a live presentation accessible on AnaptysBio’s investor website.
AnaptysBio specializes in first-in-class antibody product candidates targeting immune control mechanisms for inflammation and immuno-oncology. Their pipeline includes several innovative candidates like imsidolimab and ANB030, developed using their proprietary somatic hypermutation platform.
- None.
- None.
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Jefferies London Virtual Healthcare Conference on Tuesday, November 17, 2020, at 12:35 p.m. ET. The conference will be conducted virtually, and the presentation will be available via https://wsw.com/webcast/jeff141/anab/1804050
A live webcast of the presentation will also be available through the investor section of the AnaptysBio website at https://ir.anaptysbio.com/events. A replay of the webcast will be available for 90 days following the event.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. The Company’s proprietary anti-inflammatory pipeline includes its anti-IL-36R antibody imsidolimab, previously referred to as ANB019, for the treatment of rare inflammatory diseases, including generalized pustular psoriasis, or GPP, palmoplantar pustulosis, or PPP, EGFRi and ichthyosis; its anti-PD-1 agonist program, ANB030, for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated; its BTLA modulator program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation; and its anti-IL-33 antibody etokimab, previously referred to as ANB020, for the treatment of chronic rhinosinusitis with nasal polyps, or CRSwNP, and eosinophilic asthma. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GlaxoSmithKline, including an anti-PD-1 antagonist antibody (dostarlimab GSK4057190A), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889A) and an anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation collaboration with Bristol-Myers Squibb, including an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in clinical development.
Contact:
Dennis Mulroy
AnaptysBio, Inc.
858.732.0201
dmulroy@anaptysbio.com
FAQ
What is AnaptysBio's stock symbol?
When will Hamza Suria present at the Jefferies Healthcare Conference?
Where can I watch AnaptysBio's presentation at the Jefferies Conference?
What are AnaptysBio's key product candidates?
What is the focus of AnaptysBio's research?
